Dublin, Ireland, 5 June 2023: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology Association (EHA) 2023 Congress, June 8-11, in Frankfurt, Germany.
The aim of the study was to evaluate the effect of Epeleuton, on Sickle Cell Disease (SCD) patients red blood cells’ (RBCs) adhesion to heme-activated endothelium using a novel endothelialized microfluidic system.
The poster details can be found in the link below:
Session: 26. Sickle Cell Disease
Abstract number: P1439
Presenter: Dr. Moayed Hamza, Chief Medical Officer at Afimmune.
Summary: Under physiological flow conditions, Epeleuton decreased adhesion of SCD patient RBCs at clinically relevant concentrations by affecting both the endothelium and RBCs independently.
These findings support the clinical development of oral Epeleuton, as a potential novel therapeutic option for patients with SCD.
Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a novel synthetic fatty acid drug with FDA and EMA orphan drug designations. Epeleuton is in late-stage clinical development as an oral treatment for Sickle Cell Disease.
About Sickle Cell Disease
Sickle Cell Disease (SCD) is a lifelong rare inherited disorder that affects red blood cells. SCD affects more than 100,000 people in the United States, approximately 52,000 people in Europe, and millions of people throughout the world. It is a serious and lifelong condition, and people with SCD experience many health problems and complications. People with SCD produce unusually shaped red blood cells that don’t survive as long as healthy blood cells and can block blood vessels. Pain is the leading cause of hospitalization. The hallmarks of SCD are these acute pain crises called vaso-occlusions that are a result of insufficient oxygen reaching tissues and organs.